Patients who take medication for diabetes as the thiazolidinediones may be at greater risk of bone fractures, a new study announced.
In the study, Dr. Ian Douglas of the London School of Hygiene and Tropical Medicine and colleagues have a database of more than 6 million patients in the United Kingdom and found 1819 persons aged 40 and older who had a broken bone and was a kind prescribed thiazolidinedione. The drug was introduced in the 1990s and are used to treat type 2 diabetes.
According to the revised figures to the fact that older people tend to wear broken bones, into account, the researchers found that people taking thiazolidinediones, almost 1.5 times as many fractures were at the use of drugs as if they are not taking drugs . This risk increases the longer people took the drug.
The results confirm previous research that a link between these drugs and bone fractures is recommended. But the researchers acknowledge that the study did not follow the golden rule of research that randomly assign people taking or not taking place.
But Douglas and his colleagues concluded that the results "must be in the broader debate about the risks and potential benefits of therapy should be considered with thiazolidinediones.
In the study, Dr. Ian Douglas of the London School of Hygiene and Tropical Medicine and colleagues have a database of more than 6 million patients in the United Kingdom and found 1819 persons aged 40 and older who had a broken bone and was a kind prescribed thiazolidinedione. The drug was introduced in the 1990s and are used to treat type 2 diabetes.
According to the revised figures to the fact that older people tend to wear broken bones, into account, the researchers found that people taking thiazolidinediones, almost 1.5 times as many fractures were at the use of drugs as if they are not taking drugs . This risk increases the longer people took the drug.
The results confirm previous research that a link between these drugs and bone fractures is recommended. But the researchers acknowledge that the study did not follow the golden rule of research that randomly assign people taking or not taking place.
But Douglas and his colleagues concluded that the results "must be in the broader debate about the risks and potential benefits of therapy should be considered with thiazolidinediones.
No comments:
Post a Comment